Author

Zhenghong Liu

University of Science and Technology of ChinaORCID 0009-0002-3594-4338Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Zhenghong Liu1 paper

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

D. Danielle KamatoiD· 1 shared Dongdong WangiD· 1 shared Fanshun ZhangiD· 1 shared Jianping WengiD· 1 shared John Roger SpeakmaniD· 1 shared Meijie CheniD· 1 shared Meiming SuiD· 1 shared Mengyun XuiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

D. Danielle KamatoORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

The clinical antiprotozoal drug halofuginone promotes weight loss by elevating GDF15 and FGF21

Suowen Xu, Zhenghong Liu, Tian Tian, Wenqi Zhao, Zhihua Wang, Monan Liu, Mengyun Xu, Fanshun Zhang, Zhidan Zhang, Meijie Chen, Yanjun Yin, Meiming Su, Wenxiang Fang, Wenhao Pan, Shiyong Liu, , Jianping Weng

This study shows halofuginone, an FDA-approved drug, reduces obesity in mice by increasing FGF21 and GDF15 levels, improving metabolic health.

Science Advances · Mar 26, 2025Peer-reviewedPharmacology & Toxicology